Tuesday, July 28, 2009 - 3:30 PM
S90

Solid state fermentation: different physiology and new technology for the production of microbial products

Javier Barrios-González, Jesús G. Baños, and Roxana U. Miranda. Biotecnología, Universidad Autónoma Metropolitana, Av. San Rafael Atlixco 186, Col. Vicentina, Iztapalapa C.P. 09340, Mexico, D.F., Mexico

Industrial production of antibiotics and other secondary metabolites (SM) is conventionally performed by liquid submerged fermentation (SmF); however solid-state fermentation (SSF) is rapidly becoming an alternative industrial production system. Some years ago an Indian company started industrial-scale production of some SM by SSF. Later the FDA approved this technology for the production of metabolites for human application. Production of SM by SSF is very often associated with higher yields in shorter time periods. Moreover, some antibiotics are only produced in SSF, even though the corresponding producer fungi can grow in SmF. This different physiology in SSF is often called “physiology of solid medium”. An important manifestation of it is that high yielding strains for SmF don’t perform well in SSF; dictating the need for special strains for SSF. Recently, we developed a novel lovastatin (hipocholesterolemic) production process by SSF on an artificial inert support. In this system, physiology of solid medium is clearly manifested, as a 30-fold higher lovastatin production was obtained, compared to that obtained in SmF. Furthermore, SSF biomass displayed a 14-fold higher specific production. Later we demonstrated that this higher productivity is due to a 4-fold higher expression of lovE gene (transcription factor) and of the biosynthetic genes. We have performed basic studies on the environmental stimuli inducing these physiological changes. This has allowed us to design strain improvement methods using classical and molecular genetics. In this way, we have generated mutants and transformants displaying production increases of 80 and 125% in SSF.